Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,612,585
  • Shares Outstanding, K 112,297
  • Annual Sales, $ 320 K
  • Annual Income, $ -123,850 K
  • 60-Month Beta 1.42
  • Price/Sales 4,961.55
  • Price/Cash Flow N/A
  • Price/Book 5.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.20
  • Number of Estimates 4
  • High Estimate -0.17
  • Low Estimate -0.24
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.83 +46.08%
on 03/18/20
18.89 -23.98%
on 03/05/20
-3.13 (-17.90%)
since 02/27/20
3-Month
9.83 +46.08%
on 03/18/20
21.81 -34.16%
on 01/08/20
-7.06 (-32.96%)
since 12/27/19
52-Week
3.52 +307.95%
on 10/10/19
21.93 -34.52%
on 12/27/19
+7.94 (+123.68%)
since 03/27/19

Most Recent Stories

More News
Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced...

AUPH : 14.36 (+2.21%)
AUP.TO : 20.09 (+2.08%)
Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced...

AUPH : 14.36 (+2.21%)
AUP.TO : 20.09 (+2.08%)
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced today...

AUPH : 14.36 (+2.21%)
AUP.TO : 20.09 (+2.08%)
Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") , a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune...

AUPH : 14.36 (+2.21%)
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

--- Positive AURORA Phase 3 results with voclosporin enabling an NDA submission for the treatment of lupus nephritis ("LN") by the end of the second quarter 2020 -

AUPH : 14.36 (+2.21%)
Aurinia Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 5, 2020 / Aurinia Pharmaceuticals, Inc. (AUPH) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 5, 2020 at 4:30...

AUPH : 14.36 (+2.21%)
Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't?

Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.

AUPH : 14.36 (+2.21%)
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after the...

AUPH : 14.36 (+2.21%)
Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team

--- Recruited four seasoned executives with expertise across critical commercial functions -

AUPH : 14.36 (+2.21%)
AUP.TO : 20.09 (+2.08%)
Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual...

AUPH : 14.36 (+2.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade AUPH with:

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

2nd Resistance Point 15.31
1st Resistance Point 14.84
Last Price 14.36
1st Support Level 13.73
2nd Support Level 13.09

See More

52-Week High 21.93
Fibonacci 61.8% 14.90
Last Price 14.36
Fibonacci 50% 12.73
Fibonacci 38.2% 10.55
52-Week Low 3.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar